FierceBiotechOriginal article
{"a":[{"_":"Amgen drops early-stage obesity drug, upping pressure on MariTide","$":{"href":"/biotech/amgen-drops-early-stage-obesity-drug-upping-pressure-maritide","hreflang":"en"}}]}
negativeAMG 513MariTideNegative
AI Analysis
Summary
Amgen has discontinued development of early-stage obesity drug AMG 513, consolidating its obesity program around phase 3 candidate MariTide.
Outcome Details
Early-stage obesity drug AMG 513 development terminated
Importance:4/10
Sentiment:
-0.40
obesitydrug developmentpipelineR&D
Related Companies
Read the original article
Published by FierceBiotech on August 4, 2026 1:13 PM